How do established cardiac biomarker staging systems (MAYO2004, MAYO3b, MAYO2012) perform in patients with systemic light chain amyloidosis, particularly in the presence of renal failure and atrial arrhythmia?
This study evaluates the reliability of established cardiac biomarker staging systems in AL amyloidosis patients, specifically assessing the impact of confounding comorbidities like renal failure and atrial arrhythmias.
Systemic light chain amyloidosis is a rare and life-threatening disorder, for which accurate risk stratification is crucial. Current cardiac staging systems (MAYO2004, MAYO3b, and MAYO2012) are mainly based on biomarkers, which have uncertain reliability in the context of atrial fibrillation, arrhythmia or pacemaker stimulation as well as renal insufficiency. We compared the performance of the established staging systems with particular regard to these comorbidities in 1,224 patients with systemic light chain amyloidosis diagnosed at our center from July 2002 until March 2017. We first characterized the subsets with an estimated glomerular filtration rate
Dittrich et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: